About Low density lipoprotein receptor adapter protein 1
Low density lipoprotein receptor adapter protein 1 (LDLRAP1) is a protein
from Homo sapiens identified by UniProt accession
Q5SW96, 308 residues long.
MolForge cross-references it against 0 known binders and
120 disease associations.
Target properties
| Protein name | Low density lipoprotein receptor adapter protein 1 |
|---|
| UniProt accession | Q5SW96 |
|---|
| Gene | LDLRAP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 308 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (120)
Diseases linked to this target (Open Targets).
- homozygous familial hypercholesterolemia · score 0.77
- familial hypercholesterolemia · score 0.69
- Abnormality of the cardiovascular system · score 0.51
- Hypercholesterolemia · score 0.46
- mean platelet volume · score 0.33
- platelet count · score 0.31
- blood protein measurement · score 0.27
- platelet component distribution width · score 0.26
- lung adenocarcinoma · score 0.24
- cutaneous melanoma · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q5SW96-F1 | alphafold | PREDICTED | 69.35 | — |
Amino-acid sequence (308 residues)
MDALKSAGRA LIRSPSLAKQ SWGGGGRHRK LPENWTDTRE TLLEGMLFSL KYLGMTLVEQ PKGEELSAAA IKRIVATAKA SGKKLQKVTL KVSPRGIILT DNLTNQLIEN VSIYRISYCT ADKMHDKVFA YIAQSQHNQS LECHAFLCTK RKMAQAVTLT VAQAFKVAFE FWQVSKEEKE KRDKASQEGG DVLGARQDCT PSLKSLVATG NLLDLEETAK APLSTVSANT TNMDEVPRPQ ALSGSSVVWE LDDGLDEAFS RLAQSRTNPQ VLDTGLTAQD MHYAQCLSPV DWDKPDSSGT EQDDLFSF
Explore Low density lipoprotein receptor adapter protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets